Xiong Zhang

Sorafenib plus triplet therapy with venetoclax, azacitidine and homoharringtonine for refractory/relapsed acute myeloid leukemia with FLT3‐ITD: A multicenter phase 2 study

Yu Wang, Xuejie Jiang, F. Huang, 2023, Journal of Internal Medicine.